Drug profile · INN
pazopanib hydrochloride
VOTRIENT
pazopanib hydrochloride (VOTRIENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — pazopanib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
pazopanib hydrochloride (VOTRIENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pazopanib hydrochloride?
pazopanib hydrochloride (VOTRIENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pazopanib hydrochloride?
VOTRIENT is a marketed brand name for pazopanib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pazopanib hydrochloride?
pazopanib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.